Synutra Reports Third Quarterand First Nine Months of Fiscal 2014 Financial Results - KTRE.com | Lufkin and Nacogdoches, Texas

Synutra Reports Third Quarterand First Nine Months of Fiscal 2014 Financial Results

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Synutra International, Inc.

~ Exceeds 3Q14 Sales and Earnings Forecast

~~ Provides 4Q14 Sales and Earnings Guidance Forecast

QINGDAO, China and ROCKVILLE, Md., Feb. 10, 2014 /PRNewswire/ -- Synutra International, Inc. (NASDAQ: SYUT), ("Synutra" or the "Company"), which owns subsidiaries in China that produce, distribute and sell nutritional products for infants, children and adults, today announced financial results for the third quarter and first nine months of fiscal 2014 ended December 31, 2013.

Mr. Liang Zhang, Chairman and CEO of Synutra, commented, "We are pleased with our strong performance in the third quarter as we achieved better-than-expected results in both sales growth and earnings. The sequential increase in our branded powdered formula segment sales benefitted from seasonality effects and the early timing of the Chinese New Year, but more fundamentally, was backed by the successful execution of our Goldmining Strategy and effective marketing efforts for our specialty formula products. Our distributors increased shipment volumes and we effectively managed our gross margin pressure from rising raw material costs."

"In 2013, there were changes in the competitive landscape of China's infant formula market and continued public scrutiny of dairy companies' product quality and marketing conduct. Amidst the new market environment, Synutra differentiated itself in several ways. First, as a provider of safe and nutritious products, we continue to upgrade our production standards to comply with evolving regulations. Over the long term, our French drying facility will provide a sustainable, secure supply of high-quality raw materials. Second, as the only licensed domestic producer of medical-purpose specialty formula, we are uniquely positioned to capitalize on marketing and sales in the medical channel. This advantage has helped us regain our growth momentum. Third, in light of the Chinese government's support of industry consolidation among domestic dairy companies, the strength and quality of our brands have positioned Synutra as a favorable partner for strategic growth opportunities."

"As we enter the last quarter of our fiscal year, we will maintain our focus on prudently monitoring raw material purchases, driving greater efficiency in our operating infrastructure, and delivering profitable results." concluded Mr. Zhang.

Financial Results for the Third Quarter of Fiscal 2014 versus the Second Quarter of Fiscal 2014


Quarter Ended


QoQ Change


December 31, 2013

September 30, 2013




 (in USD 000's except per share and percentage data)






Net sales

101,034

88,556


12,478

14%







Cost of sales

60,731

49,667


11,064

22%

Gross profit

40,303

38,889


1,414

4%

Gross margin

39.9%

43.9%



-400bps







Selling and distribution expenses

12,486

13,496


(1,010)

-7%

Advertising and promotion expenses

9,769

10,763


(994)

-9%

General and administrative expenses

6,477

5,831


646

11%

Government subsidies

362

103


259

251%

Total operating expenses

28,370

29,987


(1,617)

-5%







Income from operations

11,933

8,902


3,031

34%

Operating margin

11.8%

10.1%



170bps







Net interest expense and other

2,219

2,890


(671)

-23%

Income tax expense

14

14


0


Net loss attributable to the noncontrolling interest

(287)

(75)


(212)

283%







Net income attributable to common stockholders

9,987

6,073


3,914

64%







Earnings per share – Basic

$0.17

$0.11


$0.07

64%

Net sales increased 14% to $101.0 million for the third quarter of fiscal 2014 from $88.6 million in the second quarter of fiscal 2014. Net sales from the Company's branded powdered formula segment were $86.2 million, or 85% of net sales in the quarter, compared to $71.7 million, or 81% of net sales, in the previous quarter.  By volume, sales of powdered formula products were 6,449 tons in the third quarter, compared to 5,004 tons in the previous quarter. The increase was driven by the positive effects of the Company's Goldmining strategy, discount incentives and brand diversification, as well as seasonally higher consumption of formula products. This increase in volume was offset by a small decrease in average selling price of powdered formula products, which decreased to $13,360 per ton from $14,319 per ton in the previous quarter mainly due to an extra 2.5% discount to incentivize distributors to accelerate shipments, and the increased contribution from our lower priced adult formula products which are popular gifts for the winter holiday season. Overall, discounts and rebates to distributors and retail stores remained at low levels.

Net sales from Nutritional ingredients and supplements, which is comprised of external sales of chondroitin sulfate to third parties, was $6.3 million, or 6% of net sales, in the third quarter of fiscal 2014, compared to $5.3 million, or 6% of net sales in the previous quarter. This segment performed in line with expectations and revenue recognition is timed according to terms of annual supply contracts with major customers.

Net sales from Other Products, which includes imported whole milk powder and whey protein powder sold to industrial customers, was $8.6 million, or 8% of net sales, in the third quarter of fiscal 2014, compared to $11.6 million, or 13% of net sales in the previous quarter. Synutra expects to continuously incur ancillary sales of raw milk powder/ whey protein powder due to its production methods, and such sales may vary from quarter to quarter.

Gross profit was $40.3 million in the third quarter of fiscal 2014, compared to $38.9 million in the previous quarter. Gross margin in the third quarter of fiscal 2014 was 40%, compared to 44% for the previous quarter. Powdered formula margin was 50%, down from 53% for the previous quarter, due to the rising cost of raw milk powder, as well as a higher portion of lower-margin adult formula sold in the fiscal third quarter.

Selling and distribution expenses were $12.5 million, compared with $13.5 million in the second quarter of fiscal 2014.   

Advertising and promotional expenses were $9.8 million, compared with $10.8 million in the previous quarter, reflecting reduced expenses on advertising.

General and administrative expenses were $6.5 million, compared with $5.8 million in the previous quarter.

Income from operations was $11.9 million, compared to income from operations of $8.9 million in the previous quarter.

Net income attributable to common stockholders was $10.0 million in the third quarter of fiscal year 2014, or $0.17 per basic share, compared with a net income of $6.1 million, or $0.11 per basic share, in the previous quarter.

Nine Months ended December 31, 2013 Financial Results

Net sales for the first nine months of fiscal 2014 ended December 31, 2013 increased to $271.8 million from $192.9 million in the prior year period. Net sales from branded powdered formula products increased to $225.9 million, or 83% of net sales, compared to $162.9 million, or 84% of net sales in the prior year period.

Gross profit increased 74% to $115.3 million for the first nine months of fiscal 2014 from $66.3 million in the prior year period. Gross margin was 42% compared to 34% for the prior year period.

Income from operations was $27.7 million for the first nine months of fiscal 2014, compared to a loss from operation of $20.7 million in the prior year period.

Net income attributable to Synutra International, Inc. common stockholders was $20.8 million for the first nine months of fiscal 2014, or $0.36 per basic share, compared to a net loss of $67.2 million, or $(1.17) per basic share, in the prior year period.

Balance Sheet

As of December 31, 2013, the Company had cash and cash equivalents of $61.6 million and restricted cash of $123.8 million, including the current and non-current portion.  Net account receivables decreased to $18.1 million on December 31, 2013 from $26.3 million on September 30, 2013 while the Company's sequential inventory position increased 22% to $91.8 million from $75.3 million during the same period.  Total debt was $295.2 million, including $101.5 million of short-term debt and $46.5 million of long term debt due within one year, a decrease from the total debt of $308.5 million as of September 30, 2013, which included $103.4 million of short-term debt and $79.4 million of long term debt due within one year.

Conference Call Details

The Company will hold a conference call on Tuesday, February 11, 2014 at 8:00 a.m. Eastern Time to discuss the financial results. Listeners may access the call by dialing the following numbers:

United States Toll Free:

+1 (855) 500-8701

United State Toll:

+1 (845) 675-0438

International Toll:

+ 65 6723-9385

China Toll Free:

400-120-0654

Conference ID:

35588956

A webcast and replay of the conference call will be available through the Company's IR website at www.synutra.com.

About Synutra International, Inc.

Synutra International, Inc. (Nasdaq: SYUT) is a leading infant formula company in China. It principally produces, markets and sells its products through its operating subsidiaries under the "Shengyuan" or "Synutra" name, together with other complementary brands. It focuses on selling premium infant formula products, which are supplemented by more affordable infant formulas targeting the mass market as well as other nutritional products and ingredients. It sells its products through an extensive nationwide sales and distribution network covering all provinces and provincial-level municipalities in mainland China. As of December 31, 2013, this network comprised over 670 independent distributors and over 620 independent sub-distributors who sell Synutra products in approximately 28,000 retail outlets.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our current expectations, assumptions, estimates and projections about Synutra International, Inc. and its industry. All statements other than statements of historical fact in this release are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as "anticipate," "believe," "continue," "estimate," "expect," "intend," "is/are likely to," "may," "plan," "should," "will," "aim," "potential," "continue," or other similar expressions. The forward-looking statements included in this press release relate to, among others, Synutra's goals and strategies; its future business development, financial condition and results of operations, particularly the progress on the new drying facility project in France; the expected growth of the nutritional products and infant formula markets in China; market acceptance of Synutra's products; the safety and quality of Synutra's products; Synutra's expectations regarding demand for its products; Synutra's ability to stay abreast of market trends and technological advances; competition in the infant formula industry in China; PRC governmental policies and regulations relating to the nutritional products and infant formula industries and our ability to meet governmental requirements, and general economic and business conditions in China. These forward-looking statements involve various risks and uncertainties. Although Synutra believes that the expectations expressed in these forward-looking statements are reasonable, these expectations may turn out to be incorrect. Synutra's actual results could be materially different from the expectations. Important risks and factors that could cause actual results to be materially different from expectations are generally set forth in Synutra's filings with the Securities and Exchange Commission. The forward-looking statements are made as of the date of this press release. Synutra International, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statements are made or to reflect the occurrence of unanticipated events.

FOR FURTHER INFORMATION:

Synutra International, Inc.
Investor Relations Department
ir@synutra.com or 646-328-2552

 

Synutra International, Inc.

Consolidated Balance Sheets

Dollars and shares in thousands, except per share data








December 31, 2013


March 31, 2013

ASSETS





Current Assets:





Cash and cash equivalents

$

61,553

$

79,050

Restricted cash


69,899


68,410

Accounts receivable, net of allowance


18,087


30,183

Inventories


91,832


87,707

Due from related parties


3,139


2,696

Income tax receivable


1


5

Prepaid expenses and other current assets


29,555


18,404

Assets held for sale


3,247


0






Total current assets


277,313


286,455






Property, plant and equipment, net


146,177


130,121

Land use rights, net


9,460


10,829

Intangible assets, net


3,955


4,135

Restricted cash


53,932


39,883

Due from related parties


2,602


2,981

Other assets


663


1,740






TOTAL ASSETS

$

494,102

$

476,144






LIABILITIES AND EQUITY










Current Liabilities:





Short-term debt

$

101,538

$

127,449

Long-term debt due within one year


46,535


82,663

Accounts payable


56,310


48,717

Due to related parties


1,454


1,862

Advances from customers


21,477


12,982

Other current liabilities


49,284


52,788






Total current liabilities


276,598


326,461






Long-term debt


147,105


102,164

Deferred revenue


4,237


4,402

Capital lease obligations


7,995


7,848

Other long-term liabilities


6,328


6,062






Total liabilities


442,263


446,937






Equity:





Synutra International, Inc. shareholders' equity





Common stock, $.0001 par value: 250,000 authorized; 57,301 and 57,301 issued and outstanding at December 31, 2013 and March 31, 2013, respectively


6


6

Additional paid-in capital


135,440


135,440

Accumulated deficit


(114,673)


(135,508)

Accumulated other comprehensive income


30,986


28,828






Total Synutra common shareholders' equity


51,759


28,766






Noncontrolling interest


80


441






Total equity


51,839


29,207






TOTAL LIABILITIES AND EQUITY

$

494,102

$

476,144

 

Synutra International, Inc.

Consolidated Statements of Operations

Dollars in thousands, except per share data








 Three Months Ended December 31,


 Nine Months Ended December 31,



2013


2012


2013


2012










Net sales

$

101,034

$

73,228

$

271,795

$

192,914

Cost of sales


60,731


41,717


156,522


126,628










Gross profit


40,303


31,511


115,273


66,286










Selling and distribution expenses


12,486


14,488


40,753


41,903

Advertising and promotion expenses


9,769


9,910


29,008


26,900

General and administrative expenses


6,477


6,967


18,760


21,986

Gain on disposal and liquidation of subsidiaries


0


0


367


2,610

Government subsidy


362


216


630


1,181










Income (loss) from operations


11,933


362


27,749


(20,712)










Interest expense


3,850


4,021


11,761


11,511

Interest income


1,076


604


3,186


1,681

Other income (expense), net


555


573


1,407


56










Income (loss) before income tax expense (benefit)


9,714


(2,482)


20,581


(30,486)










Income tax expense (benefit)


14


10,971


107


37,086










Net income (loss)


9,700


(13,453)


20,474


(67,572)










Net income (loss) attributable to the noncontrolling interest


(287)


(183)


(361)


(417)










Net income (loss) attributable to common stockholders

$

9,987

$

(13,270)

$

20,835

$

(67,155)










Earnings (loss) per share - basic

$

0.17

$

(0.23)

$

0.36

$

(1.17)










Weighted average common stock outstanding - basic


57,301


57,301


57,301


57,301

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
KTRE logo

KTRE

358 TV Road,
Pollok TX 75969

FCC Public File
publicfile@ktre.com
936-853-8639
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KTRE. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.